Oncoheal Healthcare LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Oncoheal Healthcare LLP Pharmaceutical Export Portfolio Dataset — 2 Products, $27.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Oncoheal Healthcare LLP — Pharmaceutical Exporter Profile (2026) | 2 Products, $27.5K Trade | TransData Nexus

Oncoheal Healthcare LLP

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $27.5K Total Trade · DGFT Verified

Oncoheal Healthcare LLP is an Indian pharmaceutical exporter with a total trade value of $27.5K across 2 products in 1 therapeutic categories. Based on 6 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cabazitaxel ($23.1K), Regorafenib ($4.4K), .

Oncoheal Healthcare LLP — Export Portfolio & Destination Treemap

Oncoheal Healthcare LLP pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Oncoheal Healthcare LLP? — Company Overview & Market Position

Oncoheal Healthcare LLP is a pharmaceutical company headquartered in Ahmedabad, Gujarat, India. Established on April 12, 2021, the company operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAW-6923. The registered office is located at 43, Stadium House, Near S P Stadium, Navrangpura, Ahmedabad, Gujarat, 380009. The company is led by two designated partners: Indravadan Himmatlal Shah and Prashant Manshukhlal Marvaniya, both appointed on May 31, 2022. Oncoheal Healthcare LLP specializes in the distribution and export of oncology and super-specialty medicines, focusing on providing high-quality, affordable treatments to global markets. The company has a workforce of 11 to 25 employees and reported an annual turnover between ₹1.5 to ₹5 crore. As of March 28, 2026, Oncoheal Healthcare LLP has been operational for approximately four years and eleven months.

What Does Oncoheal Healthcare LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Cabazitaxel$23.1K 2Regorafenib

Product Portfolio — Top 2 by Export Value

Oncoheal Healthcare LLP exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cabazitaxel	Advanced Oncology	$23.1K	3	0.2%	9
2	Regorafenib	Advanced Oncology	$4.4K	3	0.4%	10

Oncoheal Healthcare LLP exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $27.5K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Oncoheal Healthcare LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Oncoheal Healthcare LLP operates as a distributor and wholesaler of pharmaceutical products, including oncology medicines, rather than as a manufacturer. The company sources its products from various reputable manufacturers to ensure high-quality standards. Specific details regarding manufacturing plant locations, capacities, and specializations are not publicly disclosed, as Oncoheal Healthcare LLP does not engage in manufacturing activities directly.

3Key Leadership

The leadership team at Oncoheal Healthcare LLP comprises two designated partners:

Indravadan Himmatlal Shah: Appointed on May 31, 2022, he serves as a Designated Partner.

Prashant Manshukhlal Marvaniya: Also appointed on May 31, 2022, he holds the position of Designated Partner.

Both partners are actively involved in the strategic direction and operations of the company, leveraging their expertise to drive growth and maintain high standards in the pharmaceutical distribution sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Oncoheal Healthcare LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Oncoheal Healthcare LLP has engaged in exporting pharmaceutical products to various international markets, including the United States, South Korea, Bangladesh, Nepal, and Afghanistan. The company's export activities are primarily focused on oncology medicines, such as Cabazitaxel and Regorafenib, which are included in their product portfolio. While specific regulatory approvals and market access statuses in these countries are not publicly detailed, Oncoheal Healthcare LLP's commitment to quality and compliance suggests adherence to international standards. The company's focus on oncology products aligns with global health priorities, potentially facilitating market entry in regions with high demand for cancer treatments.

2Emerging Markets

Oncoheal Healthcare LLP has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's emphasis on exporting oncology medicines positions it to meet the growing demand for cancer treatments in these areas. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly disclosed, Oncoheal Healthcare LLP's adherence to international quality standards suggests a strategic approach to market penetration. The company's mission to provide high-quality, affordable treatments aligns with the healthcare needs of emerging markets, potentially enhancing its competitive position.

Oncoheal Healthcare LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As a distributor and wholesaler, Oncoheal Healthcare LLP does not manufacture pharmaceutical products; therefore, it does not hold FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company sources its products from various reputable manufacturers who are responsible for obtaining necessary FDA approvals. Specific details regarding the FDA inspection history of these manufacturing facilities are not publicly disclosed. Oncoheal Healthcare LLP's role in the supply chain is to ensure the distribution of high-quality, FDA-compliant products to its clients.

2WHO & EU GMP

Oncoheal Healthcare LLP's product portfolio includes oncology medicines such as Cabazitaxel and Regorafenib. While specific details regarding WHO prequalification or EU Good Manufacturing Practice (GMP) certifications for these products are not publicly disclosed, the company's commitment to quality suggests adherence to international standards. Oncoheal Healthcare LLP's focus on exporting to regulated markets indicates a strategic emphasis on compliance with global quality standards, potentially including WHO and EU GMP requirements.

3CDSCO & Indian Regulatory

Oncoheal Healthcare LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Oncoheal Healthcare LLP operates in a competitive pharmaceutical distribution market, with key competitors including AmerisourceBergen, Pfizer, Entero Healthcare, Target Healthcare, and CHEPLAPHARM. The company's focus on oncology medicines positions it in a specialized segment, potentially differentiating it from competitors with broader portfolios. While specific market share comparisons are not publicly available, Oncoheal Healthcare LLP's strategic emphasis on high-quality, affordable treatments aligns with global health priorities, potentially enhancing its competitive position.

2Key Differentiators

Oncoheal Healthcare LLP's key differentiators include its specialization in oncology and super-specialty medicines, a commitment to high-quality standards, and a focus on providing affordable treatments. The company's extensive network with manufacturers, dealers, wholesalers, and retailers across India enables it to supply bulk quantities of difficult-to-find drugs at competitive rates. Additionally, Oncoheal Healthcare LLP offers EMS and door-to-door delivery services through reputable freight forwarders, enhancing its distribution capabilities.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Oncoheal Healthcare LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Oncoheal Healthcare LLP's track record as a distributor and wholesaler is characterized by a focus on high-quality, affordable oncology medicines. The company's export volume and consistency are supported by its extensive network with manufacturers, dealers, wholesalers, and retailers across India, enabling it to supply bulk quantities of difficult-to-find drugs at competitive rates. Reliability indicators include the company's adherence to international quality standards and its commitment to maintaining high ethical and quality standards in its operations.

2Certifications to Verify

Importers should verify the following certifications when considering products from Oncoheal Healthcare LLP:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the manufacturer directly.

WHO-GMP Certification: Ensure that the manufacturing facilities hold World Health Organization (WHO) Good Manufacturing Practice (GMP) certification. This

Frequently Asked Questions — Oncoheal Healthcare LLP

How many pharmaceutical products does Oncoheal Healthcare LLP export from India?

Oncoheal Healthcare LLP exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Cabazitaxel ($23.1K), Regorafenib ($4.4K). Total export value is $27.5K.

What is Oncoheal Healthcare LLP's total pharmaceutical export value?

Oncoheal Healthcare LLP's total pharmaceutical export value is $27.5K, based on 6 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Oncoheal Healthcare LLP cover?

Oncoheal Healthcare LLP exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Oncoheal Healthcare LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.